Objective-LDLs include particle subclasses that have different mobilities on polyacrylamide gradient gels: to 28.5 nm), LDL-IIa (26.5 to 27.2 nm), LDL-IIb (25.6 to 26.5 nm), LDL-IIIa (24.7 to 25.6 nm), LDL-IIIb (24.2 to 24.7 nm), LDL-IVa (23.3 to 24.2 nm), and LDL-IVb (22.0 to 23.3 nm in diameter). We hypothesized that the association between smaller LDL particles and coronary artery disease (CAD) risk might involve specific LDL subclasses. Methods and Results-Average 4-year onstudy lipoprotein measurements were compared with annualized rates of stenosis change from baseline to 4 years in 117 men with CAD. The percentages of total LDL and HDL occurring within individual subclasses were measured by gradient gel electrophoresis. Annual rate of stenosis change was related concordantly to onstudy averages of total cholesterol (Pϭ0.04), triglycerides (Pϭ0.05), VLDL mass (Pϭ0.03), total/HDL cholesterol ratio (Pϭ0.04), LDL-IVb (Pϭ0.01), and HDL 3a (Pϭ0.02) and inversely to HDL 2 -mass (Pϭ0.02) and HDL 2b (Pϭ0.03). The average annual rate in stenosis change was 6-fold more rapid in the fourth quartile of LDL-IVb (Ն5.2%) than in the first quartile (Ͻ2.5%, Pϭ0.03).
H uman plasma LDLs include multiple distinct subclasses of different particle size that are separable on nondenaturing polyacrylamide gradient gels. 1 Seven LDL subclasses have been identified: LDL-I (27.2 to 28.5 nm), LDL-IIa (26.5 to 27.2 nm), LDL-IIb (25.6 to 26.5 nm), LDL-IIIa (24.7 to 25.6 nm), LDL-IIIb (24.2 to 24.7 nm), LDL-IVa (23.3 to 24.2 nm), and LDL-IVb (22.0 to 23.3 nm in diameter). 1, 2 Several case-control, nested case-control, and prospective studies have suggested that a predominance of smaller LDL particles (ie, LDL-III or LDL-IV) is associated with increased coronary heart disease (CHD) risk. [3] [4] [5] [6] [7] [8] [9] [10] The contribution of individual subclasses within LDL-III and LDL-IV to CHD risk has not been determined.
HDLs also include a heterogeneous mixture of particles of differing size that can be separated into at least 5 subclasses on nondenaturing polyacrylamide gradient gels. 11 These include HDL 3c (7.2 to 7.8 nm), HDL 3b (7.8 to 8.2 nm), HDL 3a (8.2 to 8.8 nm), HDL 2a (8.8 to 9.7 nm), and HDL 2b (9.7 to 12 nm). 11 Case-control and angiographic studies suggest that CHD risk may be increased when HDL 2b is reduced relative to HDL 3c and HDL 3b . [12] [13] [14] The rate at which coronary artery lesions progress is a risk factor for clinical coronary events. The rate of change in percent stenosis has been shown to be significantly predictive of myocardial infarctions and coronary deaths during 7-year 15 and 12-year 16 follow-up periods. The rate is also reflective of atherosclerosis elsewhere, eg, changes in carotid artery intima-media thickness. 17 Quantitative changes in coronary artery diameters and stenosis have been associated with plasma levels of total cholesterol, 18 LDL cholesterol, 18, 19 HDL cholesterol, 20,21 HDL 2 cholesterol, 20 HDL 2b , 20 LDL density, [22] [23] [24] apolipoprotein B (apo B), 18 lipoprotein(a) [Lp(a)], 18, 25 triglyceride-rich lipoprotein remnants, 21 and hepatic lipase activity. 24 The purpose of this study was to examine the relations of LDL and HDL subclasses to rates of CHD progression. Specifically, average onstudy measurements of lipoprotein subclasses were compared with annual rates of stenosis change of coronary lesions in men who remained under care of their usual physician when serving as controls in a randomized trial. 26 The analyses show that the annual rate of progression of coronary artery stenosis is related to the relative levels of specific LDL and HDL subclasses. Consistent with other reports, 22, 27 we found preliminary evidence that effects of lipoproteins on atherosclerotic progression may be related to baseline lesion severity.
Methods

Study Design
The Stanford Coronary Risk Intervention Project (SCRIP) was a 4-year, randomized, controlled clinical trial of the efficacy of multifactor risk reduction for reducing CHD progression. 26 It included a control group that remained under care of their own usual physicians during the 4-year period. The control arteriograms at baseline and after 4 years and the lipoprotein subclass measurements taken during the intervening 4 years provide the data for this report.
Eligible participants were recruited between February 1984 and March 1987 for this 4-year intervention trial. They were required to be Ͻ75 years old and free of severe congestive heart failure, pulmonary disease, intermittent claudication, or noncardiac lifethreatening illness. After arteriography, patients were treated medically, received percutaneous transluminal coronary angioplasty, or had coronary artery bypass graft surgery, in accordance with standard clinical indications. Subjects remained eligible for the study if (1) at least 1 major coronary artery had a segment with luminal narrowing between 5% and 69% that was unaffected by the revascularization procedures and (2) the left ventricular ejection fraction was at least 20%. Randomization into treatment or control (usual care) conditions occurred after baseline evaluations (however, data from the control group only are analyzed in this report). All subjects were scheduled for 4 annual medical and risk-factor evaluations and a follow-up coronary arteriography at the fourth year. The study protocol and progress reports were reviewed before the start of the study and annually thereafter by the Stanford University Panel on Human Subjects in Medical Research and the Committee for the Protection of Human Subjects at the University of California. Because men and women have different LDL profiles 28 and the number of female subjects in SCRIP was small (nϭ29), only men were analyzed in the current report. This study was carried out in full compliance with the University of California and Stanford University Committees for the Protect of Human Subjects.
Quantitative Arteriography
Arteriograms were made by the patient's attending physician using a uniform protocol. Specifically, these used catheters with metallic size markers, prior nitroglycerin administration, and replication of projection angles. 26 Follow-up arteriograms were obtained within a 6-week window of the patient's fourth-year anniversary of his baseline arteriogram. The segment quantifications on baseline and follow-up films used identical projections from the single plane that best visualized each segment. An automatic edge-finding algorithm defined the edges of the calibrating catheter and the coronary vessels. 26 A reference diameter was defined to compute percent stenosis in diseased segments.
All assessable portions of the coronary vessels Ͼ1.5 mm in diameter on the baseline arteriograms were divided into 0.5-to 3.5-cm segments. Qualifying segments had to have clearly quantifiable lumen margins and along with the proximal vessel, could not contain lesions having 70% or greater diameter reduction. Vessels that had been grafted or instrumented by a prior revascularization procedure were also excluded. To ensure comparable measurements of the quantification segments on serial arteriograms, segments were defined by either proximal or distal fiducial points and by absolute length. Clinically mandated coronary arteriograms obtained during the study were performed under this same protocol. When a vessel containing a qualifying segment was affected by a subsequent revascularization procedure, the quantification results for that segment up to the last available preprocedure arteriogram were then used. Qualifying segments that were totally occluded on follow-up arteriography were coded as 100% stenosis, and segments distal to total occlusion were considered lost to follow-up.
Lipid, Lipoprotein, Glucose, and Insulin Measurements
At baseline and annually thereafter, fasting plasma lipids were measured at 2 clinic visits, usually within 2 weeks of each other. The 2 values were averaged for each subject to represent the subject at baseline and for each year in the study. Plasma concentrations of total cholesterol and triglycerides were measured by enzymatic procedures (ABA 200 instrument, Abbott Laboratories). 29 HDL cholesterol was measured by the dextran sulfate-magnesium precipitation of apo B-containing lipoproteins, followed by enzymatic determination of cholesterol. 30, 31 The laboratory remained certified by the Centers for Disease Control and Prevention Lipid Standardization Program throughout the study. Lp(a) and LDL plus IDL in apo B dϾ1.006 g/mL lipoproteins were separated by ultracentrifugation, 32 and the infranatant was collected and stored at Ϫ70°C for subsequent analysis by ELISA. 33, 34 Plasma glucose concentration was measured with the glucose oxidase method 35 and insulin concentration, by radioimmunoassay 36 after an overnight fast and 1 hour after administration of a 100-g oral glucose load.
Electrophoresis of LDL in whole plasma and HDL in the dՅ1.20 g/mL fraction was performed on a Pharmacia electrophoresis apparatus (GE 4-II Pharmacia) and slab gradient gels (PAA 2/16 and PAA 4/30, respectively; Pharmacia). 1,2 Lipid staining for LDL was performed by incubating the gels overnight in a 50°C to 60°C oven in a solution of 945 mL 95% ethanol, 555 mL distilled water, and 0.61 g oil red O stain. Protein-stained gels for HDL were obtained by agitating the gels in a 50-to 75-mL solution of 0.04% Coomassie G-250 and 3.5% perchloric acid after fixing the protein in 10% sulfosalicylic acid for 1 hour. The gels were scanned with a model RFT densitometer (Transidyne Corp) at wavelengths of 555 nm for the lipid-stained gels and 603 nm for the protein-stained gels. 1 Analyses are based on the percentage of the total LDL (22.0 to 28.5 mm) and HDL (7.2 to 12.0 nm) represented by each subclass. Analytic ultracentrifugation was used to measure concentrations of total lipoprotein mass within multiple regions for HDL 3 (F 1.20 0 to 3.5), HDL 2 (F 1.20 3.5 to 9), small LDL (S f 0 to 7), large LDL (S f 7 to 12), IDL (S f 12 to 20), and VLDL mass concentrations (S f 20 to 400). 37 One hundred seventeen of the 139 men (84%) randomized to receive their usual physician's care had follow-up arteriograms. These occurred, on average (meanϮSD), 3.97Ϯ0.45 years after their baseline arteriogram. Exposure of the arteries to lipoproteins was estimated by averaging plasma lipoprotein values for all available clinic visits. Nearly all subjects had lipid and lipoprotein measurements available at all 5 annual visits (1 man had data from 4 visits and 2 men had data from 3 visits). A decision was made not to collect plasma for detailed lipoprotein subfraction and subclass measurements at the third annual visit. From the remaining 4 clinic visits, all available data were used to compute onstudy averages for analytic ultracentrifuge measurements of lipoprotein mass (4 annual visits in 101 men, 3 visits in 13 men, and 2 visits in 3 men) and gradient gel measurements of HDL subclasses (4 visits in 95 men, 3 visits in 19 men, and 2 visits in 3 men). The analyses of gradient gel estimates of LDL subclasses are limited to baseline and fourth-year data from 106 men.
Statistical Analysis
The annual rate of stenosis change was averaged for all diseased segments within each individual. Least-squares regression was used to test for significant associations between the annual rate of stenosis change (the dependent variable) and the onstudy average lipoprotein, body mass index, resting heart rate, and blood pressure levels (the independent variables) during the 4-year study. Multiple regression analysis was used to test for a significant association between the rate of stenosis change and average percent LDL-IVb after adjustment for other onstudy measurements, and stepwise regression analysis was used to select the best regression model for predicting change in stenosis. Significant associations were verified by the nonparametric Spearman rho. An ANOVA test for trend was used to test for increasing (or decreasing) mean annual rate of stenosis when the observations were partitioned by quartiles of the average onstudy lipoprotein levels. We also tested whether baseline levels of stenosis affected the relations of onstudy lipoproteins to the annualized rate of stenosis change. The 364 diseased segments were separated into 2 categories (184 segments each) according to whether or not baseline stenosis was less than the median (medianϭ30% stenosis). Within each category, the change in the rate of stenosis was averaged for all qualifying segments within each individual. There were 96 men with 1 or more diseased segments with Ͻ30% stenosis at baseline (meanϮSD, 21.81Ϯ4.79%) and 86 men with 1 or more diseased segments with 30% or greater stenosis at baseline (meanϮSD, 39.39Ϯ6.16%). The annual rate of stenosis change was not related in the segments having Ͻ30% and those having Ն30% stenosis at baseline (rϭ0.09, Pϭ0.46 in 65 men having both types of segments). All significance levels are 2-sided. Table 1 presents the characteristics of the sample. On average, the men were in their fifth decade, moderately over- Sample sizes: 117 men for stenosis, body mass index, resting heart rate, blood pressure, plasma lipids, lipoproteins, analytic ultracentrifuge lipoprotein mass measurements, fasting insulin and glucose, and gradient gel electrophoresis of HDL subclasses; 112 men for 1-hour glucose and insulin, 106 men for gradient gel measurements of LDL-subclasses, and 97 men for Lp(a) and ApoB.
Results
weight, mostly nonhypertensive, and had only moderately elevated plasma lipids. Forty-two men (35.9%) had average LDL cholesterol levels Ն160 mg/dL, and 20 men (17.1%) had average HDL cholesterol levels Ͻ35 mg/dL. Twelve men were hypertensive, as defined by either systolic blood pressure Ն140 mm Hg or diastolic blood pressure Ն90 mm Hg. Eighteen men had average onstudy fasting plasma glucose concentrations Ͼ7.0 mmol/L. During the study, only 12% of the men ever took bile acid-binding resins, 13.7% ever took niacin, 8.5% ever took fibric acid compounds, and only 7.7% ever took a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor.
The annualized rate of stenosis change from baseline to 4 years was unrelated to average onstudy smoking status (Pϭ0.99), daily cigarette consumption (Pϭ0.68), heart rate (Pϭ0.95), systolic blood pressure (Pϭ0.75), diastolic blood pressure (Pϭ0.77), body mass index (Pϭ0.06), treadmill test duration (Pϭ0.91), and postchallenge insulin (Pϭ0.13) and glucose (Pϭ0.10) concentrations in plasma. Table 2 shows that the rate of stenosis change was significantly related to fasting glucose (Pϭ0.0008) and insulin (Pϭ0.02). The association between stenosis and onstudy fasting glucose was significant for the 18 men with onstudy glucose Ն7.0 mmol/L (slopeϮSE, 0.53Ϯ0.20, Pϭ0.02) but not for the 90 men with levels Ͻ7.0 mmol/L (0.15Ϯ0.36, Pϭ0.67). Table 2 also presents the regression slopes relating annual rates of stenosis change to average onstudy plasma lipid and lipoprotein concentrations and percent distributions of LDL and HDL subclasses. Average plasma concentrations of total cholesterol and triglycerides and the average ratio of total cholesterol to HDL cholesterol were all related concordantly to the annual rate of stenosis change. Although the inverse relation between plasma HDL cholesterol concentrations and rate of stenosis change failed to achieve statistical significance (Pϭ0.11), average HDL 2b levels were inversely related to annual rates of stenosis change (Pϭ0.03). Average LDL cholesterol and small-LDL mass (ie, S f 0 to 7) also failed to achieve statistically significant concordant relations with the annual rate of stenosis change. However, rates of stenosis change were associated significantly with onstudy averages for the percentages of total LDL within the LDL-IVb interval (Pϭ0.01) and marginally with onstudy averages for LDL-IIIb (Pϭ0.06). Nonparametric Spearman's correlations confirmed the significant associations of the annual rate of stenosis change with average LDL-IVb (ϭ0.19, Pϭ0.05), total cholesterol (ϭ0.25, Pϭ0.008), VLDL mass, and triglycerides (both ϭ0.19, Pϭ0.04). There was also a significant Spearman correlation between annual rate of stenosis change and plasma concentrations of small-LDL mass averaged over 4 years (ϭ0.18, Pϭ0.05). Table 3 presents the regression slopes for the annual rate of stenosis change versus plasma lipoproteins, glucose, and insulin concentrations by baseline stenosis levels. This was done to assess whether (1) the associations observed in Table  2 applied to all segments regardless of the extent of disease and (2) the effects of LDL subclasses on disease progression differed from those of other lipoproteins. In diseased segments with Ͻ30% stenosis at baseline, the annual rate of stenosis change was associated concordantly with fasting glucose, LDL-IIIb, and LDL-IVb and inversely with LDL-IIb (Table 3 ). In diseased segments with Ն30% stenosis at baseline, the annual rate of stenosis change was associated concordantly with fasting glucose and insulin, total cholesterol, total/HDL cholesterol, and HDL 3b and inversely with HDL 2 mass and HDL 2b (Table 3 ). Nonparametric Spearman's correlations confirmed the significant associations of the annual rate of stenosis change with average LDL-IVb (ϭ0.25, Pϭ0.02) and LDL-IIb (ϭ-0.27, Pϭ0.01) in segments having Ͻ30% stenosis at baseline and of the annual rate of stenosis change with total/HDL cholesterol (ϭ0.21, Pϭ0.05) and HDL 3b (ϭ0.22, Pϭ0.04) in segments having more disease. Figure 1 displays the mean annual rate of stenosis change by quartiles of LDL-IVb. The cut points were taken at average onstudy LDL-IVb proportions of 2.5%, 3.7%, and 5.2% of total LDL. There was a significant trend for more rapid stenosis from the first to the fourth quartile (Pϭ0.04). The annual rate of stenosis change was 6-fold more rapid in the fourth quartile than in the first quartile of LDL-IVb (Pϭ0.03 for difference in means). The association was more pronounced in the segments with Ͻ30% stenosis at baseline and nonexistent in the segments with greater baseline disease. Finally, we examined the regression slope between average onstudy LDL-IVb and annual rates of stenosis change in all diseased segments when adjusted for other lipoproteins. The association remained significant at PՅ0.05 with only 2 minor exceptions: adjustment for LDL-IIIb and HDL 3a , each of which reduce the significance levels from Pϭ0.01 to Pϭ0.06. The relation also persisted when adjusted for body mass index (adjusted slopeϮSE, 0.208Ϯ0.094, Pϭ0.03), fasting insulin (0.221Ϯ0.092, Pϭ0.02), fasting glucose concentra-tions (0.210Ϯ0.090, Pϭ0.02), diabetes, and duration of use of bile acid-binding resins, niacin, fibric acid compounds, and HMG CoA reductase inhibitors. The association between annual rates of stenosis change and LDL-IVb remained significant when adjusted for segments with Ͻ30% baseline stenosis and remained consistently nonsignificant for segments with greater disease (analyses not displayed).
When stepwise multiple regression analysis was used to select the best-fitting lipoprotein model for predicting the annual rate of stenosis change in all diseased segments, the best model included only 1 variable: average onstudy LDL-IVb. Once LDL-IVb was entered into the model, none of the other lipoprotein variables improved prediction of the rate of stenosis change. Including fasting insulin and glucose among the candidate independent variables resulted in the selection Sample size: 96 men had at least one diseased segment with Ͻ30% stenosis at baseline, and 86 men had at least one diseased segment with Ն30% or greater stenosis at baseline. Rates for segments were averaged within each individual.
of both fasting glucose (Pϭ0.007) and LDL-IVb (Pϭ0.02). When LDL-IVb was excluded from the model, then the best model for predicting the change in stenosis was onstudy HDL 3a , which had a somewhat less fit than LDL-IVb (|R|ϭ0.22 vs |R|ϭ0.25)
Discussion
Although LDL-IVb represents only a minor fraction of lipid-stained LDL (Ͻ10%), these analyses suggest that the percentage of LDL contained within this subclass may be the strongest lipoprotein predictor for the annual rate in stenosis change. Total cholesterol, triglycerides, and the ratio of total cholesterol to HDL cholesterol did not predict annual increases in percent stenosis once the effects of LDL-IVb were removed (ie, their nonselection in a stepwise regression analysis). Compared with men in the lowest quartile of LDL-IVb, those in the highest quartile had annual rates of stenosis change that were 6-fold more rapid (Figure 1) . The association between annual stenosis change rates and LDL-IVb persisted when tested nonparametrically, showing that the association was not due to isolated outliers. The association appeared to specifically involve those diseased segments having less stenosis at baseline. Others have reported that onstudy concentrations of the least-buoyant LDL particle (S f 0 to 3) were associated with annual rates in stenosis change, 22 particularly in segments exhibiting less-severe baseline stenosis. We have shown elsewhere that gradient gel electrophoresis provides greater resolution of the effects involving LDL-IVb compared with analytic ultracentrifugation. 28 The identification of LDL-IVb as the LDL species most strongly related to atherosclerosis progression was unexpected, because onstudy means are likely to be less precise for LDL-IVb than the other lipoprotein measurements. Specifically, the measurement error for an onstudy mean will decrease with the square root of the number of clinic visits used in its calculation. Whereas triglycerides, total cholesterol, and lipoprotein cholesterol were generally calculated as the average for 10 clinic visits and HDL subclasses and analytic ultracentrifuge measurements were calculated as the average of 4 clinic visits, LDL subclasses were calculated for 2 visits only.
There is evidence to suggest that LDL-IVb includes a distinct class of LDL particle that is not simply the "trailing" portions of LDL-IIIa or LDL-IIIb. LDL-IVb was initially described on the basis of minor LDL peaks and inflection points appearing within this region. 2 In a previous report involving other male subjects, we identified a number of significant correlations between the LDL-IVb subclass and other lipoprotein parameters. 28 The strengths of these correlations were within the ranges of those observed for the predominant LDL-II and LDL-III subclasses and these lipoproteins. These included significant positive correlations of LDL-IVb with plasma concentrations of triglycerides and apo B. Plasma LDL-IVb levels were also significantly correlated with LDL cholesterol and IDL mass (positively) and with apo A-I and HDL cholesterol (negatively). LDL-IVb was also significantly higher after than before puberty in males and higher after than before menopause in females. 38 In contrast, the intervening subclass, LDL-IVa, showed correlations with other lipoproteins that were weaker than those observed for the flanking LDL-IVb or LDL-IIIb regions and showed no significant difference before and after male puberty or female menopause.
The present findings are consistent with previous studies indicating that smaller peak LDL particle size is predictive of increased risk for myocardial infarction 6,39 -42 and that angiographic progression of coronary artery disease is related to increased LDL density. 24 (However, the association between small LDL and coronary artery disease is not always observed. [43] [44] [45] [46] [47] ) The present findings suggest that LDL-IVb, as well as possibly LDL-IIIb, may explain a major portion of the risk for coronary artery disease previously attributed to small, dense LDL.
Several mechanisms have been postulated for the greater atherogenicity of dense than buoyant LDL. Smaller, denser LDL is more readily oxidized than larger LDL. 48 Oxidation of LDL leads to the generation of macrophage-derived foam cells and fatty streak formation in the arterial intima. LDLs of 1.051ՅdՅ1.065 g/mL have a lower free-cholesterol content and oxidative resistance than lighter LDLs, 49 which is consistent with the inverse correlation between LDL free-cholesterol content and oxidizability. 50 LDL-IVb's high phosphatidylcholine to free-cholesterol ratio and packed apo B-100 conformation also may increase LDL-IVb's cholesteryl ester hydroperoxide susceptibility to oxidation. 49 Other factors that could increase LDL atherogenicity include uptake in arterial Mean annual rate of stenosis change of coronary artery lesions by quartiles of mean onstudy LDL-IVb in 106 men. The cut points were taken at average onstudy LDL-IVb proportions of 2.5%, 3.7%, and 5.2%. *Significantly less than the fourth quartile.
tissue (inversely related to particle size 51 ) and prolonged and enhanced retention by the arterial wall (greater in dense than buoyant LDL 52 ). Increased postprandial lipemia 53 and increased insulin resistance 54 are also associated with small LDL and may contribute to its atherogenic risk. It remains to be determined, however, whether these mechanisms show a sufficient gradation with LDL size and density to account for LDL-IVb's apparent atherogenic properties, given its low plasma levels. Albers et al 55 have identified HDL 1 and Lp(a) in addition to small LDL within LDL S f 0 to 2, which might also contribute to the atherogenicity of the LDL-IVb subclass. However, Lp(a) was not found to be related to the annual rate of stenosis change ( Table 2 ).
The status of elevated, nondiabetic, fasting glucose levels as a risk factor for CHD remains controversial. 56, 57 We observed a significant association between fasting plasma glucose concentrations and the rate of stenosis change that was mostly attributed to men with fasting levels of 7.0 mmol/L or greater. Our results therefore agree with other reports that suggest that the increase in CHD risk is restricted to the upper percentiles of the fasting glucose distribution 58, 59 and not with those that suggest a linear increase throughout the range of glucose values. 60, 61 In summary, this report identified a relation of coronary disease progression with LDL-IVb, which may predominate over other lipoprotein risk predictors despite being a minor LDL constituent. Although angiography cannot routinely differentiate between stenosis caused by clot or atheroma, the results of the quantitative arteriograms are probably specific to the atherogenic process per se, because the patients were not selected for unstable symptoms that are often precipitated by thrombus formation. However, caution may be warranted when generalizing these results, given that (1) we excluded from the analyses revascularized arteries and arteries either free of stenosis or with 70% or greater stenosis at baseline; (2) segments with 100% stenosis precluded our ability to evaluate segments distal to the total occlusion; and (3) 24.8% of the men randomized to receive their usual physician's care were excluded from the analyses owing to missing follow-up arteriograms or lipoprotein measurements. The current findings require independent confirmation, because LDL-IVb was not identified a priori for hypothesis testing and the testing of multiple hypotheses leads to a simultaneous significance level above the nominal 5%.
High LDL-IVb levels belong to a cluster of associated lipoprotein disorders that include low HDL cholesterol (including elevated HDL 3b and low HDL 2b ) and elevated triglycerides. 62 Identifying the contribution of each component is problematic because they seldom occur in isolation, and statistical techniques are required to parse their independent and shared contributions. These techniques will tend to discount the contribution of those variables that are difficult to estimate because of either laboratory error or their variability within individuals. This would seem to be apropos of the interpretation of LDL-IVb. Because of its paucity, LDL-IVb is difficult to measure. Moreover, onstudy LDL-IVb was estimated from only 2 clinic visits. Thus, selecting LDL-IVb as the aspirant pathogen in the stepwise regression analysis may underestimate its true significance. The provision of standardized measurement of minor LDL-IVb may thus enhance the assessment and management of coronary disease risk.
